Seroprevalence of SARS-CoV-2 (COVID-19) among healthcare workers in Saudi Arabia: comparing case and control hospitals

被引：59

作者：

Alserehi, Haleema Ali ^{[1
]}

Alqunaibet, Ada Mohammed ^{[1
]}

Al-Taw, Jaffar A. ^{[2
,3
,4
]}

Alharbi, Naif Khalaf ^{[5
,6
]}

Alshukairi, Abeer Nizar ^{[7
]}

Alanazi, Khalid Hamdan ^{[8
]}

Bin Saleh, Ghada Mohammed ^{[8
]}

Alshehri, Amer Mohammed ^{[9
]}

Almasoud, Abdulrahman ^{[5
]}

Hashem, Anwar M. ^{[10
,11
]}

Alruwaily, Amaal Rabie ^{[1
]}

Alaswad, Rehab Habeeb ^{[1
]}

Al-Mutlaq, Hind Mohammed ^{[1
]}

Almudaiheem, Abdulllah Ali ^{[1
]}

Othman, Fatmah Mahmoud ^{[12
]}

Aldakeel, Sumyah Abdullah ^{[9
]}

Abu Ghararah, Mouath Rashid ^{[9
]}

Jokhdar, Hani Abdulaziz ^{[13
]}

Algwizani, Abdullah Rshoud ^{[14
]}

Almudarra, Sami Saeed ^{[1
]}

Albarrag, Ahmed Mohammed ^{[9
,15
]}

机构：

[1] Saudi Ctr Dis Prevent & Control, Execut Dept Res, Execut Dept Global Hlth Epidemiol Surveillance &, Riyadh, Saudi Arabia

[2] Johns Hopkins Aramco Healthcare, Specialty Internal Med & Qual & Patient Safety De, Infect Dis Unit, Dhahran, Saudi Arabia

[3] Indiana Univ Sch Med, Div Infect Dis, Dept Med, Indianapolis, IN 46202 USA

[4] Johns Hopkins Univ, Sch Med, Dept Med, Div Infect Dis, Baltimore, MD 21205 USA

[5] King Abdullah Int Med Res Ctr, Dept Infect Dis Res, Vaccine Dev Unit, Riyadh, Saudi Arabia

[6] King Saud bin Abdulaziz Univ Hlth Sci, Riyadh, Saudi Arabia

[7] King Faisal Specialist Hosp & Res Ctr, Dept Med, Jeddah, Saudi Arabia

[8] Minist Hlth, Infect & Control Dept, Riyadh, Saudi Arabia

[9] Saudi Ctr Dis Prevent & Control, Publ Hlth Lab, Riyadh, Saudi Arabia

[10] King Abdulaziz Univ, Fac Med, Dept Med Microbiol & Parasitol, Jeddah, Saudi Arabia

[11] King Abdulaziz Univ, King Fahd Med Res Ctr, Vaccines & Immunotherapy Unit, Jeddah, Saudi Arabia

[12] King Saud bin Abdulaziz Univ Hlth Sci, Coll Appl Med Sci, Res Dept, Riyadh, Saudi Arabia

[13] Minist Hlth, Publ Hlth, Riyadh, Saudi Arabia

[14] Saudi Ctr Dis Control & Prevent, Riyadh, Saudi Arabia

[15] King Saud Univ, Sch Med, Dept Pathol, Riyadh, Saudi Arabia

来源：

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE | 2021年 / 99卷 / 03期

关键词：

SARS-CoV-2; COVID-19; seroprevalence; serology; healthcare workers; RISK-FACTORS; INFECTION;

D O I：

10.1016/j.diagmicrobio.2020.115273

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Healthcare workers (HCWs) stand at the frontline for fighting coronavirus disease 2019 (COVID-19) pandemic. This puts them at higher risk of acquiring the infection than other individuals in the community. Defining immunity status among health care workers is therefore of interest since it helps to mitigate the exposure risk. This study was conducted between May 20th and 30th, 2020. Eighty-five hospitals across Kingdom of Saudi Arabia were divided into 2 groups: COVID-19 referral hospitals are those to which RT-PCR-confirmed COVID-19 patients were admitted or referred for management (Case-hospitals). COVID-19 nonaffected hospitals where no COVID-19 patients had been admitted or managed and no HCW outbreak (Control hospitals). Next, seroprevalence of severe acute respiratory syndrome coronavirus 2 among HCWs was evaluated; there were 12,621 HCWs from the 85 hospitals. There were 61 case-hospitals with 9379 (74.3%) observations, and 24 control-hospitals with 3242 (25.7%) observations. The overall positivity rate by the immunoassay was 299 (2.36%) with a significant difference between the case-hospital (2.9%) and the control-group (0.8%) (P value <0.001). There was a wide variation in the positivity rate between regions and/or cities in Saudi Arabia, ranging from 0% to 6.31%. Of the serology positive samples, 100 samples were further tested using the SAS2pp neutralization assay; 92 (92%) samples showed neutralization activity. The seropositivity rate in Kingdom of Saudi Arabia is low and varies across different regions with higher positivity in case-hospitals than control-hospitals. The lack of neutralizing antibodies (NAb) in 8% of the tested samples could mean that assay is a more sensitive assay or that neutralization assay has a lower detection limits; or possibly that some samples had cross-reaction to spike protein of other coronaviruses in the assay, but these were not specific to neutralize severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). (C) 2020 Elsevier Inc. All rights reserved.

引用

页数：5

共 32 条

[1] Healthcare-associated infections: the hallmark of Middle East respiratory syndrome coronavirus with review of the literature [J].

Al-Tawfiq, J. A. ;

Auwaerter, P. G. .

JOURNAL OF HOSPITAL INFECTION, 2019, 101 (01) :20-29

[2] Serologic testing of coronaviruses from MERS-CoV to SARS-CoV-2: Learning from the past and anticipating the future [J].

Al-Tawfiq, Jaffar A. ;

Memish, Ziad A. .

TRAVEL MEDICINE AND INFECTIOUS DISEASE, 2020, 37

[3]

Al-Tawfiq Jaffar A, 2020, Infez Med, V28, P64

[4] Humoral Immunogenicity and Efficacy of a Single Dose of ChAdOx1 MERS Vaccine Candidate in Dromedary Camels [J].

Alharbi, Naif Khalaf ;

Qasim, Ibrahim ;

Almasoud, Abdulrahman ;

Aljami, Haya A. ;

Alenazi, Mohamed W. ;

Alhafufi, Ali ;

Aldibasi, Omar S. ;

Hashem, Anwar M. ;

Kasem, Samy ;

Albrahim, Raed ;

Aldubaib, Musaad ;

Almansour, Ali ;

Temperton, Nigel J. ;

Kupke, Alexandra ;

Becker, Stephan ;

Abu-obaidah, Ali ;

Alkarar, Ali ;

Yoon, In-Kyu ;

Azhar, Esam ;

Lambe, Teresa ;

Bayoumi, Faisal ;

Aldowerij, Ali ;

Ibrahim, Osman H. ;

Gilbert, Sarah C. ;

Balkhy, Hanan H. .

SCIENTIFIC REPORTS, 2019, 9 (1)

[5]

Almasaud A, 2020, METHODS MOL BIOL, V2099, P117, DOI 10.1007/978-1-0716-0211-9_10

[6]

Alonso-Lopez M, 2020, SARS COV 2 INFECT HL, DOI 10.1101/2020.04.07.20055723

[7] Risk Factors for Middle East Respiratory Syndrome Coronavirus Infection among Healthcare Personnel [J].

Alraddadi, Basem M. ;

Al-Salmi, Hanadi S. ;

Jacobs-Slifka, Kara ;

Slayton, Rachel B. ;

Estivariz, Concepcion F. ;

Geller, Andrew I. ;

Al-Turkistani, Hanan H. ;

Al-Rehily, Sanaa S. ;

Alserehi, Haleema A. ;

Wali, Ghassan Y. ;

Alshukairi, Abeer N. ;

Azhar, Esam I. ;

Haynes, Lia ;

Swerdlow, David L. ;

Jernigan, John A. ;

Madani, Tariq A. .

EMERGING INFECTIOUS DISEASES, 2016, 22 (11) :1915-1920

[8]

Barranco Rosario, 2020, Med Leg J, V88, P65, DOI 10.1177/0025817220923694

[9]

Barrett Emily S, 2020, medRxiv, DOI 10.1101/2020.04.20.20072470

[10] Symptoms and immunoglobulin development in hospital staff exposed to a SARS-CoV-2 outbreak [J].

Brandstetter, Susanne ;

Roth, Samra ;

Harner, Susanne ;

Buntrock-Doepke, Heike ;

Toncheva, Antoaneta A. ;

Borchers, Natascha ;

Gruber, Rudolf ;

Ambrosch, Andreas ;

Kabesch, Michael .

PEDIATRIC ALLERGY AND IMMUNOLOGY, 2020, 31 (07) :841-847

← 1 2 3 4 →